Efung Capital

CEO Zhu Pai is the public face of the firm and the named investment leader, recognized repeatedly by Chinese industry rankings including CVInfo's Top 50 Nova Star Investor in 2025 and Forbes China's Best Young Investors in 2026. The firm's website lists a core management and investment team, but specific decision-making governance — such as an investment committee structure — is not publicly disclosed.

Efung is a pure-play life sciences specialist. Since its 2012 pivot, it has invested exclusively in biomedical companies, with a particular emphasis on innovative drugs and high-end medical devices. It does not maintain a consumer internet, enterprise software, or advanced manufacturing practice, which distinguishes it from the multi-sector venture firms that dominate Chinese private equity.

The firm self-reports coverage from seed and early-stage startup rounds through growth equity and pre-IPO. Publicly confirmed deals span early innovation (Aridis Pharmaceuticals), growth-stage drug platforms (Ascentage Pharma), and pre-IPO positions that have fed a consistent IPO pipeline from 2019 through 2026 across the STAR Board and Hong Kong Stock Exchange.

Yes. In 2017, the firm formally launched a cross-border investment initiative and has since backed US-based biotech companies, including Aridis Pharmaceuticals and Centrexion Therapeutics. The domestic RMB fund remains the core vehicle, but the firm has built a repeatable pathway for sourcing and diligencing ex-China life sciences assets.

Efung does not publicly market a co-investment or fund-of-funds program. Its disclosed model is direct deal-by-deal investing. The 2025 strategic cooperation agreement with China's National Venture Capital Guidance Fund suggests the firm is willing to co-invest alongside state-guided capital, but standard LP-GP co-investment rights alongside third-party managers are not a publicized part of its strategy.

The parent entity is a Shenzhen-based limited partnership. Efung also established Hainan Efung Junma Private Fund Management in 2021, an entity registered with the Asset Management Association of China, to expand its onshore private fund management capabilities and comply with evolving Chinese regulations on private investment vehicles.

Efung's website and public disclosures document a dense IPO track record since 2019. Portfolio companies that have listed include Qyuns Therapeutics, Sunho Biotech, and Huahao Zhongtian in 2024, and Ascentage Pharma, Cloudbreak Pharma, Healthytide Biotech in 2025, with Beixin Life Sciences completing an IPO in early 2026. The firm treats consistent public-market exits as a core KPI.